Companies › Alessa Therapeutics
2 active drug programs in 19 registered trials: 7 Phase 1, 7 Phase 2, 4 Phase 3, 1 Phase 4; Oncology, Genitourinary; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Bicalutamide Androgen Receptor antagonist | AR | Phase 1 | Prostate Adenocarcinoma; Androgen Deprivation Therapy; Prostate Cancer; Castration Levels of Testosterone … | Apr 2027 |
| Enzalutamide Androgen Receptor antagonist | AR | Phase 1 | Prostate Adenocarcinoma | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03090165 | Bicalutamide | Phase 1 | Triple Negative Breast Cancer | Oncology | Oct 2026 |
| NCT02605486 | Bicalutamide | Phase 1 | Metastatic Breast Cancer (MBC) | Oncology | Nov 2026 |
| NCT07393867 | Bicalutamide | Phase 2 | Intermediate Risk Prostate Cancer | Oncology | Dec 2026 |
| NCT03650894 | Bicalutamide | Phase 2 | Breast Neoplasm Female | Oncology | Dec 2026 |
| NCT00223145 | Bicalutamide | Phase 3 | Prostate Cancer | Oncology | Dec 2026 |
| NCT00544830 | Bicalutamide | Phase 2 | PSA Level Greater Than Two | Oncology | Feb 2027 |
| NCT04943536 | Bicalutamide | Phase 1 | Prostate Adenocarcinoma | Oncology | Apr 2027 |
| NCT05327647 | Bicalutamide | Phase 2 | Non-Muscle Invasive Bladder Cancer | Oncology | May 2027 |
| NCT05095207 | Bicalutamide | Phase 1 | Breast Cancer | Oncology | Jun 2027 |
| NCT06222593 | Bicalutamide | Phase 1 | Carcinoma, Renal Cell | Oncology | Jul 2027 |
| NCT05100472 | Bicalutamide | Phase 2 | Prostate Cancer | Oncology | Oct 2027 |
| NCT06365788 | Bicalutamide | Phase 2 | Triple Negative Breast Neoplasms | Oncology | Dec 2027 |
| NCT07117851 | Bicalutamide | Phase 2 | Extramammary Paget Disease | Oncology | Dec 2027 |
| NCT05521698 | Bicalutamide | Phase 1 | Non-Muscle Invasive Bladder Urothelial Carcinoma | Oncology | Jun 2028 |
| NCT07848828 | Bicalutamide | Phase 4 | Androgen Deprivation Therapy | Genitourinary | Jul 2028 |
| NCT06257693 | Enzalutamide | Phase 1 | Prostate Adenocarcinoma | Oncology | Dec 2028 |
| NCT05019846 | Bicalutamide | Phase 3 | Prostate Cancer | Oncology | Dec 2029 |
| NCT05781217 | Bicalutamide | Phase 3 | Prostate Cancer | Oncology | Dec 2032 |
| NCT03678025 | Bicalutamide | Phase 3 | Castration Levels of Testosterone | Oncology | Apr 2033 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.